Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Fibroadenoma 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Diseases 1

Interventions

Letrozole 7Fluorodeoxyglucose F18 7Magnetic Resonance Spectroscopy 5Blood Specimen Collection 5pembrolizumab 4atezolizumab 4Trastuzumab 4Oncolytic Virotherapy 4Bevacizumab 4palbociclib 3Saline Solution 3Fish Oils 3Docosahexaenoic Acids 3Denosumab 3Carboplatin 3Biopsy 3pertuzumab 2olaparib 2Vitamin D 2Vinorelbine 2Taxes 2Sentinel Lymph Node Biopsy 2Radiotherapy 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Omacor 2Neoadjuvant Therapy 2Metformin 2Lapatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Breast Neoplasms × gadoterate meglumine × Clear all
NCT04341129 2023-12-05

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

University of Chicago

Phase EARLY_PHASE1 Completed
50 enrolled
Breast

Breast Diseases, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Fibroadenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡